You are here

Article Text

Article menu

Download PDFPDF

Extended report
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005
  1. L Annemans1,2,3,
  2. E Spaepen1,
  3. M Gaskin4,
  4. M Bonnemaire5,
  5. V Malier5,
  6. T Gilbert6,
  7. G Nuki7
  1. 1
    IMS Health, Brussels, Belgium
  2. 2
    Department of Public Health, Ghent University, Ghent, Belgium
  3. 3
    School of Pharmacy, Brussels University, Brussels, Belgium
  4. 4
    IMS Health, London, UK
  5. 5
    Ipsen, Paris, France
  6. 6
    Ipsen, Milford, Massachusetts, USA
  7. 7
    University of Edinburgh Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK
  1. Professor L Annemans, Ghent University, Faculty of Medicine, Department of Public Health, Building A, 2nd Floor, De Pintelaan 185, 9000 Ghent, Belgium; Lieven.Annemans{at}UGent.be

Abstract

Objective: To investigate and compare the prevalence, comorbidities and management of gout in practice in the UK and Germany.

Methods: A retrospective analysis of patients with gout, identified through the records of 2.5 million patients in UK general practices and 2.4 million patients attending GPs or internists in Germany, using the IMS Disease Analyzer.

Results: The prevalence of gout was 1.4% in the UK and Germany. Obesity was the most common comorbidity in the UK (27.7%), but in Germany the most common comorbidity was diabetes (25.9%). The prevalence of comorbidities tended to increase with serum uric acid (sUA) levels. There was a positive correlation between sUA level and the frequency of gout flares. Compared with those in whom sUA was <360 μmol/l (<6 mg/dl), odds ratios for a gout flare were 1.33 and 1.37 at sUA 360–420 μmol/l (6–7 mg/dl), and 2.15 and 2.48 at sUA >530 μmol/l ( >9 mg/dl) in the UK and Germany, respectively (p<0.01).

Conclusions: The prevalence of gout in practice in the UK and Germany in the years 2000–5 was 1.4%, consistent with previous UK data for 1990–9. Chronic comorbidities were common among patients with gout and included conditions associated with an increased risk for cardiovascular disease, such as obesity, diabetes and hypertension. The importance of regular monitoring of sUA in order to tailor gout treatment was highlighted by data from this study showing that patients with sUA levels ⩾360 μmol/l (⩾6 mg/dl) had an increased risk of gout flares.

http://dx.doi.org/10.1136/ard.2007.076232

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: LA has received an unrestricted research grant from Ipsen. MB and VM are Ipsen employees. TG is a former Ipsen employee. ES, MG, GN: no competing interests.

    • Funding: Financial support for this study was provided by Ipsen. Involvement by Ipsen in the study design, in the collection, analysis and interpretation of data, and in the writing of the report and the decision to submit for publication was limited to the role of the authors employed by Ipsen.